Investing
Philip Morris to sell Vectura for $198 million after health shift criticism By Reuters
(Reuters) -Philip Morris International’s Vectura Fertin Pharma said on Tuesday it would sell its asthma inhaler maker Vectura Group to Molex Asia Holdings for 150 million pounds ($198 million).
Marlboro maker PMI bought Vectura in September 2021 as part of a plan to transform itself into a “broader healthcare and wellness” group, a shift it says has been hampered by critics.
PMI acquired Vectura, part of its health and wellness unit, in a deal worth 1.1 billion pounds. It has since taken a $680 million impairment against the unit and abandoned plans to raise $1 billion in net revenues from the division by 2025.
Jacek Olczak, PMI’s CEO, said that while it remained committed to driving innovation in inhaled medications, Phillips Medisize, operated by Molex, was better placed to lead Vectura.
It would also release Vectura from “the unreasonable burden of external constraints and criticism related to our ownership,” he said.
PMI, whose shares were down 1.4% at 1233 GMT, said the deal also included potential deferred payments of up to 148 million pounds.
($1 = 0.7572 pounds)
Read the full article here
-
Side Hustles7 days ago
San Francisco Pizzeria Found Success With Unique Menu
-
Side Hustles5 days ago
United Airlines Adding Starlink, Free WiFi to All Flights
-
Passive Income6 days ago
Correct Your Spelling Errors on PDFs With This All-in-One PDF Tool
-
Side Hustles6 days ago
There’s a Burnout Crisis in American Workplaces — and This Is the Solution
-
Passive Income4 days ago
Reduce Your Business Expenses With This $30 Microsoft Office Alternative
-
Side Hustles7 days ago
Who Are the Billionaires Backing Trump or Harris?
-
Personal Finance5 days ago
Inflation hits 2.5% in August, keeping the Fed on track to lower interest rates
-
Investing7 days ago
Top EU privacy regulator opens probe into Google’s AI compliance By Reuters